Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.

TitreClinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
Publication TypeJournal Article
Year of Publication2010
AuthorsNichita, C, Stelle, M, Vavricka, S, Ali, AEl-Wafa, Ballabeni, P, de Saussure, P, Straumann, A, Rogler, G, Michetti, P
JournalDigestion
Volume81
Issue2
Pagination78-85
Date Published2010
DOI10.1159/000253855
ISSN1421-9867
Mots-clésAdult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Crohn Disease, Female, Humans, Logistic Models, Male, Phenotype, Retrospective Studies, Severity of Illness Index, Smoking, Switzerland, Treatment Outcome
Abstract

BACKGROUND: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice.

AIM: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD.

METHODS: We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of 3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response.

RESULTS: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4-6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4-6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall.

CONCLUSION: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/20093835?dopt=Abstract

Alternate JournalDigestion
Citation Key / SERVAL ID2857
PubMed ID20093835

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top